



HHS Public Access

Author manuscript

Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2020 July 01.

Published in final edited form as:

Cancer Epidemiol Biomarkers Prev. 2020 January ; 29(1): 103–111. doi:
10.1158/1055-9965.EPI-19-0169.

Evaluation of Tobacco Smoke and Diet as Sources of Exposure to Two Heterocyclic Aromatic Amines for the U.S. Population: NHANES 2013–2014

Li Zhang^{1,*}, Lanqing Wang¹, Yao Li¹, Yang Xia¹, Cindy M. Chang², Baoyun Xia¹, Connie S. Sosnoff¹, Brittany N. Pine¹, B. Rey deCastro¹, Benjamin C. Blount^{1,*}

¹Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, 4770 Buford Highway Mail Stop F47, Atlanta, GA 30341.

²Office of Science, Center for Tobacco Products, U.S. Food and Drug Administration, Silver Spring, MD 20993

Abstract

Background: Heterocyclic aromatic amines (HAAs) are a group of hazardous substances produced during combustion of tobacco or high-temperature cooking of meats. 2-Amino-9H-pyrido[2,3-b]indole (AαC) is a major carcinogenic HAAs in tobacco smoke.

Methods: Urinary AαC, used as a marker of AαC exposure, was analyzed on spot urine samples from adult participants of the 2013-2014 cycle of the National Health and Nutrition Examination Survey (NHANES; N=1,792). AαC was measured using isotope-dilution liquid chromatography–tandem mass spectrometry. Exclusive combusted tobacco smokers were differentiated from non-users of tobacco products through both self-report and serum cotinine data.

Results: Among exclusive smokers, sample-weighted median urinary AαC was 40 times higher than non-users. Sample-weighted regression models showed that urinary AαC increased significantly with serum cotinine among both exclusive tobacco users and non-users with second-hand smoke exposure. Among non-users, eating beef cooked at high temperature was associated with a significant increase in urinary AαC, while consuming vegetables was associated with decreased AαC. In addition, smoking one-half pack of cigarettes per day was associated with a significant increase of 23.6 pg AαC/mL calculated at geometric mean of AαC, controlling for potential confounders. In comparison, increase in AαC attributable to consuming the 99th percentile of beef cooked at high temperature was 0.99 pg AαC/mL.

* **Corresponding Authors:** Li Zhang and Benjamin C. Blount, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, 4770 Buford Highway MS F47, Atlanta, GA 30341. Phone: 770-488-4212. LZhang6@cdc.gov, bkb3@cdc.gov.

Publisher's Disclaimer: Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of CDC and FDA. Use of trade names and commercial sources is for identification only and does not constitute endorsement by the U.S. Department of Health and Human Services, CDC or FDA.

Disclosure of Potential Conflicts of Interest

The authors declare no potential conflicts of interest.

Conclusions: Both exclusive smokers and non-users of tobacco in the general U.S. population are exposed to AαC from tobacco smoke, with additional, lesser contributions from certain dietary components.

Impact: AαC is an important biomarker that is associated with tobacco smoke exposure.

Keywords

Biomarkers of exposure; Heterocyclic Aromatic Amines; Tobacco Smoke; Diet

Introduction

Tobacco use is the single largest preventable cause of disease and death in the United States, and tobacco smoking is responsible for more than 480,000 deaths each year in the United States (1). A significant body of evidence accumulated over several decades suggests that tobacco smoke exposure is related to development of lung cancer and other cancers (1–4). Various carcinogens have been identified in tobacco smoke (4–6).

Heterocyclic aromatic amines (HAAs) are a group of hazardous substances produced during burning of tobacco or high-temperature cooking of meats (7–10). HAAs are amines that contain at least one heterocyclic ring and one aromatic ring (Supplementary Figure S1). HAAs are strongly mutagenic and carcinogenic in various *in vitro* and *in vivo* models. HAAs can induce tumors in various organs, including mammary glands, prostate, lungs, colon, skin, bladder, and liver (11–14). Epidemiological studies associate frequent HAA exposure with elevated cancer risk (15–17). The International Agency for Research on Cancer (IARC) categorized a number of HAAs as possible (Group 2B) and probable (Group 2A) human carcinogens (18).

Among more than 25 HAAs so far identified (19), 2-amino-9H-pyrido[2,3-b]indole (AαC, Group 2B carcinogen) is one of most abundant carcinogenic HAAs in tobacco smoke (10). AαC levels in tobacco smoke can reach as high as 260 ng per cigarette (7,10,20,21). This approaches the levels of other well-known carcinogens in tobacco smoke, such as N'-nitrosonornicotine (NNN), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and benzo[α]pyrene (BaP) (5,22,23).

Another carcinogenic HAA detected in tobacco smoke is 2-amino-3-methyl-9H-pyrido[2,3-b]indole (MeAαC, Group 2B carcinogen) (Supplementary Figure S1). MeAαC is a methyl homolog of AαC. MeAαC levels in tobacco smoke are about 10-fold lower than AαC levels (7,8,10). These two HAAs are carcinogenic in animal models (5,24–28), and IARC classifies AαC and MeAαC as suspected human carcinogens (29). Additionally, the U.S. Food and Drug Administration (FDA) lists AαC and MeAαC as harmful and potentially harmful constituents (HPHCs) in tobacco products and tobacco smoke (30). Besides tobacco smoke, AαC and MeAαC can form in foods prepared at high temperatures (approximately 200°C–300°C), such as barbecued, fried, or broiled meats, poultry, and fish (8,31–34).

Metabolic activation has been proposed as a mechanism for the carcinogenicity of AαC and MeAαC (9,35). Cytochrome P450 enzymes are involved in the oxidation of the exocyclic

amine group of A α C and MeA α C (35–37). Sequentially, these N²-hydroxylated metabolites of A α C and MeA α C can be further catalyzed by acetyltransferases, sulfotransferases, or glucuronosyltransferases to generate reactive O-esters that could bind covalently to DNA and elicit genotoxicity (38–43).

Although the potential for A α C and MeA α C to harm human health is well documented, few studies have evaluated human exposure to these two carcinogens. A small-scale study (170 subjects) conducted in China documented that A α C was consistently detected in smokers' urine. The number of cigarettes smoked per day was positively associated with urinary levels of A α C in study participants (44). A U.S. study (30 subjects) detected A α C in most of the urine samples of smokers, but those levels had dropped 87% after 6 weeks of not smoking (45). Even fewer studies have measured MeA α C in human biospecimens. The aim of this report is to characterize human exposure to A α C and MeA α C in the general population. We measured A α C and MeA α C as urinary biomarkers of exposure to these carcinogenic HAAs as part of the National Health and Nutrition Examination Survey (NHANES), which conducts biomonitoring of the United States civilian, non-institutionalized population.

Materials and Methods

Study Design

NHANES is a national survey that assesses population health and nutritional status based on data collected from a cross-sectional, multistage probability sample that is representative of the non-institutionalized U.S. civilian population. As part of Centers for Disease Control and Prevention (CDC), the National Center for Health Statistics (NCHS) is responsible for conducting NHANES and collecting questionnaire data, physical examination data, and biospecimens from participants. The NCHS Research Ethics Review Board reviewed and approved the study, and informed written consent was obtained from all participants before they took part in the study.

Spot urine samples were collected during physical examinations carried out in a mobile examination center (MEC) from participants aged 18 years in the NHANES 2013–2014 survey cycle. We subsequently measured urinary A α C and MeA α C in a special one-third sample of MEC participants (NHANES dataset HCAAS_H; N = 2,605) that included all adult smokers in the 2013–2014 cycle. Results reported here, however, are from a subset of these participants who met eligibility criteria and for whom all required data were present (this attrition is detailed in *Identifying Users of Combusted Tobacco and Non-Users of Tobacco* below).

Analytical Method

Spot urine samples were stored at –70°C before assay. The total urinary concentrations of A α C and MeA α C (free and conjugated forms) were analyzed using isotope-dilution liquid chromatography–tandem mass spectrometry (LC/MS/MS) and robotic sample preparation (46). Briefly, an aliquot of 0.5 mL of urine samples was spiked with internal standards that are stable isotope analogs of targeted analytes. The conjugated forms of A α C and MeA α C in the samples were hydrolyzed at base condition for 5 hr. After hydrolysis, the total urinary

A α C and MeA α C were extracted from urine matrix by using diatomaceous earth and mixed mode of cation exchange solid phase extraction plates, respectively. The throughput and precision of sample preparation was improved through automated solid phase extraction using an integrated robotic system (46). Analytes were chromatographically resolved from urinary interferences using a reversed phase column (Agilent Zorbax Eclipse Plus C18, 2.1 \times 100 mm 3.5 μ m; Santa Clara, CA, USA). A α C and MeA α C in the samples were detected by AB Sciex API 5500 QTRAP system (Framingham, MA, USA). The limits of detection of A α C and MeA α C were 0.62 pg/mL and 0.33 pg/mL, respectively. Serum cotinine was measured by using LC/MS/MS (47).

Low-concentration and high-concentration quality control materials and blank urines were run together with NHANES 2013–2014 samples to evaluate method performance on the day of analysis. The reported data satisfy the accuracy and precision requirements of the quality control/quality assurance program of the CDC National Center for Environmental Health, Division of Laboratory Sciences (48). Measurements below the limit-of-detection were substituted with the limit of detection divided by the square-root of two (49,50).

Identifying Users of Combusted Tobacco and Non-Users of Tobacco

Exclusive combusted tobacco smokers were differentiated from non-users of tobacco products through both self-report and serum cotinine data (51,52), which is detailed in Supplementary Information. Attrition of participants for statistical analysis is as follows: missing serum cotinine data (146 participants), use of smokeless tobacco and nicotine replacement therapy (135 participants), or missing data for other variables involved in regression models (532 participants). This attrition resulted in 1,792 study participants eligible for statistical analysis for A α C and 1,793 study participants for MeA α C. For the cigarettes smoked per day (CPD) regression model described below, 32 additional participants were excluded for missing CPD data leaving 1,760 study participants.

Statistical Analysis

NHANES recruits participants by using a multistage, probability sampling design. This complex design must be accounted for in order to estimate variances correctly and to achieve unbiased, nationally representative statistics. Robust estimation can be made by implementing survey sample weights (NHANES Special Sample weight; WTFSM) on each participant's data and performing Taylor series linearization. This estimation approach was conducted in the statistical software applications SUDAAN®, Version 11.0.0 (Research Triangle Institute, Research Triangle Park, NC) and SAS® 9.4 (SAS Institute Inc. Cary, NC). Data from the NHANES 2013 – 2014 sampling cycle were analyzed with sample-weighted linear regression models that was stratified by tobacco use status (exclusive smokers vs. non-users). Parameters, including absolute change in biomarker concentration (Y) relative to the j th predictor X_j , from these models were estimated as described in detail in Supplementary Information.

Sample-weighted regression models were stratified by smoking status, and a collection of demographic variables as follows were included as predictors: sex, age, race/Hispanic origin, body mass index (BMI), impoverishment (poverty income ratio < 1.00, indicating

self-reported family income below the U.S. Census poverty threshold), and fasting time (delta time between the time of specimen collection and last consumption of anything other than water). Except for BMI, information for these potential confounders was self-reported. The reference group was male for sex and non-Hispanic white for race/Hispanic origin. Age in years was divided into ranges: 18–39, 40–59, and ≥60, with 40–59 years as the reference group. For adults ≥20 years BMI was defined using standardized cut-points: underweight (BMI < 18.5), healthy weight (18.5 ≤ BMI < 25), and overweight/obese (BMI ≥ 25). Participants < 20 years were identified as underweight, healthy weight, and overweight/obese if they were below the 5th percentile, between the 5th and 85th percentile, and above the 85th percentile, respectively, for their sex and age (www.cdc.gov/healthyweight/assessing/bmi/adult_bmi/index.html).

Cotinine is a metabolite of nicotine, the primary addictive ingredient in tobacco products. Cotinine in human serum is a highly specific biomarker of tobacco smoke exposure. With a half-life of 16–18 hours, cotinine is suitable for biomarker studies concerning recent tobacco use (52). Serum cotinine was included as a continuous predictor to reflect tobacco smoke exposure. Among tobacco non-users, tobacco smoke exposure is attributable to secondhand tobacco smoke (SHS). SHS exposure can be assessed based on serum cotinine concentrations. In addition, we tested direct association of urinary biomarker concentrations with frequency of tobacco smoking. To run this test, unstratified, sample-weighted regression models where serum cotinine was replaced with a measure of exposure comprising self-reported average number of cigarettes smoked per day (CPD) over the five days preceding the NHANES physical exam. Tobacco smoke exposure in the CPD models was divided into five groups. Group 1 (unexposed to tobacco smoke) included participants with the ranges of < 0.05 ng/mL serum cotinine; Group 2 (presumptively exposed to secondhand tobacco smoke) included participants with the range of >0.05 to < 10 ng/mL serum cotinine; Group 3, 4, 5 included participants who consumed 1–10 CPD (0.5 pack), 11–20 (1 pack), and >20 (>1 pack), respectively. The group of unexposed participants was assigned as the reference category. The unexposed category was designated as < 0.05 ng/mL serum cotinine, which was its limit of detection in the 1999–2000 NHANES cycle. To allow historical comparison of serum cotinine results, we kept using the limit of detection at 0.05 ng/mL for definition of unexposed participants, though this was improved in 2001 to 0.015 ng/mL.

Exposure through diet is another potential source of AαC, especially when food is prepared at high temperature (31,33,34). Dietary exposure was assessed based on the amount participants consumed within each U.S. Department of Agriculture (USDA) food group for the 24-hr period (midnight to midnight) (51), which is described in detail in Supplementary Information. For this assessment, two additional food subgroups were distinguished because of their potential for high AαC exposure arising from high temperature (i.e., broiling, baking, or frying) during preparation (34): high-temperature cooked beef and high-temperature cooked fish. Double counting was avoided by subtracting the amount consumed in each subgroup from the amount consumed in their respective food group. Supplementary Table S1 details the USDA food codes and logic for apportioning dietary intake.

Quantitative analysis of urinary biomarker concentration data must account for normal physiologic variations in urine dilution, which can vary markedly for an individual between voids and thereby confound statistical inference (53). One approach to minimize this problem is to normalize the urinary concentrations of the biomarker to creatinine, which is formed endogenously by lean muscle tissue and cleared by the kidneys into urine at a relatively constant rate. Summary statistics of urinary concentrations are reported as the ratio of AαC and MeAαC to creatinine (ng/g creatinine), and urinary creatinine concentration is included as a continuous predictor in regression models to adjust for potential confounding from urine dilution.

In order to compare the exposure through diet and smoking, we estimated the absolute change in urinary HAA (ΔY) predicted for these two routes under conservative assumptions of exposure. For diet, we estimated the change in urinary HAA in pg/mL associated with consuming the sample-weighted 99th percentile daily amount of specific food groups in the United States. This dietary exposure is then readily compared to the change in urinary HAA, also in units of pg/mL, associated with smoking one-half pack of cigarettes per day from the CPD model.

Results

Sample-weighted demographic distributions of NHANES 2013–2014 participants (AαC: N = 1,792, MeAαC: N = 1,793) were summarized in Table 1. Among these participants, AαC was detected in 61.5 percent of participants, but only in 30.6 percent for MeAαC, so MeAαC was excluded from multiple regression analysis. By comparison, AαC and MeAαC were detected at much higher rates (98.9% and 75.6%, respectively) in exclusive tobacco smokers than those in non-users (39.5 % for AαC and 4.2% for MeAαC). Among exclusive smokers, urinary AαC and MeAαC concentrations were significantly correlated, with a sample-weighted Pearson correlation of 0.788. The sample-weighted median of urinary AαC among exclusive smokers was 40 times higher than non-users (31.90 vs. 0.79 ng/g creatinine, respectively; Table 2). Geometric means and selected percentiles of urinary AαC concentrations for U.S. population were summarized in Supplementary Table S2 and S3. The difference in urinary concentrations of MeAαC in exclusive tobacco smokers and non-users at selected percentiles was summarized in Supplementary Table S4 and S5. The percent-distribution of urinary AαC and MeAαC depicted these differences among exclusive smokers and non-users (Figure 1).

The sample-weighted multiple regression model among exclusive smokers (Table 3) found that urinary AαC was positively associated with serum cotinine (0.113 pg AαC/mL per ng cotinine/mL), controlling for sex, age, race/Hispanic origin, BMI, fasting time, urinary creatinine, diet, and impoverishment. Mexican-American exclusive smokers had significantly lower AαC in comparison with non-Hispanic White exclusive smokers. Urinary AαC level among impoverished exclusive smokers was significantly higher than among non-impoverished participants.

Among non-users of tobacco products (Table 4), urinary AαC was positively associated with serum cotinine (0.140 pg AαC/mL per ng cotinine/mL), presumptively attributable to

secondhand smoke exposure, controlling for sex, age, race/Hispanic origin, BMI, fasting time, urinary creatinine, diet, and impoverishment. Non-Hispanic Black and Other/Multi-Racial non-users had lower AaC than non-Hispanic White non-users. Urinary AaC was also positively associated with the amount consumed (kg) of beef cooked under high temperature (15.5 pg/mL per kg), whereas the association with consumption of fish cooked at high temperature was not significant. Consumption of vegetables (-0.264 pg/mL per kg) was a significant negative predictor of urinary AaC. Fasting time also was negatively associated with AaC.

In the un-stratified, sample-weighted CPD regression model for non-users and exclusive smokers (Supplementary Table S6), each CPD exposure group had significantly higher urinary AaC levels compared with those of non-users whose serum cotinine levels were <0.05 ng/mL, controlling for sex, age, race/Hispanic origin, BMI, fasting time, urinary creatinine, diet, and impoverishment. Figure 2 displays the sample-weighted least-square means of urinary AaC from the CPD model by exposure category, where it can be seen that urinary AaC increased in a dose-dependent manner across exposure categories.

Discussion

From a national, population-based study, we show that tobacco smoke and diet are significantly associated with AaC exposure. Sample-weighted linear regression models showed that serum cotinine was a significant positive predictor of urinary AaC among both exclusive smokers and non-users. Moreover, we found a significant dose-dependent association between exclusive smokers' urinary AaC levels and CPD smoked. Our findings for tobacco smoke exposure among both exclusive smokers and non-users is consistent with the fact that AaC is the most abundant carcinogenic HAAs in tobacco smoke (7,10,20,21), and indicated that tobacco smoke is a major source of AaC exposure in the U.S. population.

Only three small-scale studies previously reported human AaC exposure levels. A study in China (78 subjects) found that the mean of total urinary concentrations of AaC (free and conjugated forms) for smokers (20 ng/g creatinine) was significantly higher than that for nonsmokers (7 ng/g creatinine) (54). Compared with above study, median urinary AaC was slightly higher for exclusive smokers (31.90 ng/g creatinine) and much lower for non-users (0.79 ng/g creatinine) in the NHANES 2013–2014 samples. The lower median urinary AaC of non-user in our study could be related to lower levels of second-hand smoke exposure in the U.S. than in China. Another study in China measured free urinary AaC in 170 volunteers (44). The mean urinary AaC among light (1–19 CPD) smokers was 7.50 ng/g creatinine (9.2 pg/mL urine) and among heavy (>20 CPD) smokers it was 11.92 ng/g creatinine (13.8 pg/mL urine), while mean urinary AaC among nonsmokers was 2.54 ng/g creatinine. In contrast to Turesky et al. 2007, we observed higher exposure levels to AaC at corresponding CPD (least squared means 1–10 CPD: 14.0 pg/mL; 11–20 CPD: 37.2 pg/mL; >20 CPD: 64.1 pg/mL). These differences may be explained, at least in part, to differences in sample preparation. Turesky et al. 2007 measured free AaC in non-hydrolyzed samples, whereas our measurements were preceded by hydrolysis, which enables measurement of both free and base-sensitive conjugated species of AaC, thereby leading to systematically higher measured concentrations. In addition, there is large variation of AaC in cigarettes

between manufacturers that would increase the observed variation in urinary AαC at the same CPD consumed in the two countries (Manabe et al. 1991; Smith et al. 2004; Zhang et al. 2011). Nonetheless, both studies corroborated that urinary AαC followed a dose response pattern with CPD. In one small U.S. study (30 subjects) where urinary AαC measurements comprised both free and base-sensitive conjugated species (45), the measurements had magnitudes closer to ours. Konorev et al. 2015 observed that mean urinary AαC among smokers decreased from 24.3 ng/g creatinine to 3.2 ng/g creatinine after subjects had stopped smoking tobacco for six weeks.

In the NHANES 2013-2014 population, urinary AαC in non-Hispanic White smokers was around 7-fold higher than that in Mexican American smokers (Table 2). The effect of race/Hispanic origin cannot be completely explained by differences in tobacco smoke exposure alone because serum cotinine was included in the model. Difference in toxicokinetics may partly contribute to the race/Hispanic origin-related differences. CYP1A2 is one of the major P450 isoforms responsible for AαC metabolism (35,55–57). N-hydroxylation of the exocyclic amine group results in HONH-AαC, and ring oxidation of AαC at the C-3 and C-6 positions results in AαC-3-OH and AαC-6-OH, respectively (35,56). Various factors such as sex, race/Hispanic origin, and smoking status can affect CYP1A2 activity (58–60). Unfortunately, standards for these compounds and their corresponding stable isotope-labeled internal standards are not commercially available, so hydroxylated metabolites of AαC were not included in our assay. Therefore, the influence of race/Hispanic origin on AαC metabolism remains unclear and awaits future investigation.

We also found that certain diet components are significantly associated with AαC exposure. Beef and fish cooked at high temperature have been regarded as the most likely sources of AαC from foods eaten in the United States (34). Based on the formation mechanism, AαC is produced from pyrolysis of proteins or amino acids heated at high temperature (8). In the non-user and CPD regression models, eating beef cooked at high temperature was shown to be significantly associated with increased urinary AαC. In contrast, we found no significant association between urinary AαC and the amount of “meat, poultry, fish, and mixture” eaten without also specifying meat types or cooking temperature, which is consistent with a process requiring high temperature to contribute to dietary AαC exposure.

Eating vegetables was associated with significantly diminished urinary AαC levels in nonsmokers. Either decreased HAA absorption or enhanced hepatic elimination of HAA via induced CYP2A1 activity from eating vegetables has been proposed to explain reduced urinary HAA in persons who ate cooked meat (61,62). Because the hydroxylated AαC metabolites formed by CYP2A1 were not measured in our assay, we cannot say whether the influence of eating vegetables on urinary HAA levels in previous studies could be directly used to interpret our findings.

Fasting time was a significant negative predictor of urinary AαC levels in non-users of tobacco products, indicating that urinary excretion of AαC declined with time after the last meal. Because the AαC half-life is around 3.0 hr (63), urinary AαC levels would be expected to decline rapidly after complete AαC absorption from the food matrix.

We compared the potential influence of diet vs. smoking on urinary AaC by estimating the 99th percentile of beef consumption cooked at high temperature for the United States population, which we found to be 0.22 kg/day. At this level of consumption, we estimated the likely increase in urinary AaC \pm 95% CI to be 0.99 [0.16, 2.29] pg AaC/mL, compared to the increase associated with smoking one-half pack of cigarettes per day of 23.6 [18.7, 29.6] pg AaC/mL. Under these assumptions, the likely level of dietary exposure is considerably lower than from exclusive cigarette smoking.

Dietary exposure was based on 24-hour recall data collected in the MEC, thus reflecting dietary consumption for a single day. Although interviewers elicited recall with structured questions and standardized techniques, retrospective responses are generally susceptible to recall bias.

So far, no population-based study has identified tobacco smoke as a source of MeAaC exposure. A study in China lacked sufficient sensitivity of the urinary MeAaC assay to detect MeAaC in smokers (54). With the improved sensitivity of MeAaC measurement in our assay, our analysis provides the first population-based data on MeAaC. MeAaC was found to co-occur with AaC at about 10-fold lower content in tobacco smoke (7,8,10). As with AaC, MeAaC was mostly detected in smokers at around 20 times lower levels than those of AaC. Moreover, urinary AaC and MeAaC concentrations were significantly correlated among exclusive smokers with a sample-weighted Pearson correlation of 0.788. Therefore, MeAaC could serve as a valuable ancillary biomarker to assess AaC exposure.

In the United States, urinary AaC is significantly associated with serum cotinine levels among both exclusive smokers and non-users of tobacco, and tobacco smoke is a major source of AaC exposure in the general population. Much smaller increases in urinary AaC were associated with secondhand smoke exposure and eating beef cooked at high temperature.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

The authors thank the Center for Tobacco Products at FDA for providing funds for this project. We also thank James McGuffey, Ernest McGahee, Tonya Guillot, Binnian Wei, Erin Wade, Justin Brown, Stephen Arnstein, John Lee, and Christina Brosius for their suggestions and support during this study.

ABBREVIATIONS

HAAs	Heterocyclic aromatic amines
AaC	2-amino-9H-pyrido[2,3-b]indole
MeAaC	2-amino-3-methyl-9H-pyrido[2,3-b]indole
NHANES	National Health and Nutrition Examination Survey
LC/MS/MS	liquid chromatography-tandem mass spectrometry

PIR	poverty-income ratio
CPD	cigarettes smoked per day
USDA	U.S. Department of Agriculture
BMI	body mass index

References:

1. HHS. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General — Executive Summary. US Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2006 doi NBK44324 [bookaccession].
2. Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. *Br Med J* 1950;2(4682): 739–48. [PubMed: 14772469]
3. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004;328(7455):1519 doi 10.1136/bmj.38142.554479.AE. [PubMed: 15213107]
4. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. *The Lancet Oncology* 2002;3(8):461–9 doi 10.1016/S1470-2045(02)00815-X. [PubMed: 12147432]
5. Hecht SS. Research opportunities related to establishing standards for tobacco products under the Family Smoking Prevention and Tobacco Control Act. *Nicotine Tob Res* 2012;14(1):18–28 doi 10.1093/ntr/ntq216. [PubMed: 21324834]
6. Smith CJ, Perfetti TA, Garg R, Hansch C. IARC carcinogens reported in cigarette mainstream smoke and their calculated log P values. *Food Chem Toxicol* 2003;41(6):807–17 doi S0278691503000218 [pii]. [PubMed: 12738186]
7. Manabe S, Tohyama K, Wada O, Aramaki T. Detection of a carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), in cigarette smoke condensate. *Carcinogenesis* 1991;12(10): 1945–7. [PubMed: 1934275]
8. Matsumoto T, Yoshida D, Tomita H. Determination of mutagens, amino-alpha-carbolines in grilled foods and cigarette smoke condensate. *Cancer Lett* 1981;12(1-2):105–10. [PubMed: 7272995]
9. Turesky RJ, Le Marchand L. Metabolism and biomarkers of heterocyclic aromatic amines in molecular epidemiology studies: lessons learned from aromatic amines. *Chem Res Toxicol* 2011;24(8):1169–214 doi 10.1021/tx200135s. [PubMed: 21688801]
10. Zhang L, Ashley DL, Watson CH. Quantitative analysis of six heterocyclic aromatic amines in mainstream cigarette smoke condensate using isotope dilution liquid chromatography-electrospray ionization tandem mass spectrometry. *Nicotine Tob Res* 2011;13(2):120–6 doi ntq219 [pii] 10.1093/ntr/ntq219. [PubMed: 21173043]
11. Sugimura T Overview of carcinogenic heterocyclic amines. *Mutat Res* 1997;376(1-2):211–9. [PubMed: 9202758]
12. Sugimura T. Nutrition and dietary carcinogens. *Carcinogenesis* 2000;21(3):387–95. [PubMed: 10688859]
13. Nagao M A new approach to risk estimation of food-borne carcinogens--heterocyclic amines-- based on molecular information. *Mutat Res* 1999;431(1):3–12. [PubMed: 10656481]
14. Shirai T, Sano M, Tamano S, Takahashi S, Hirose M, Futakuchi M, et al. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. *Cancer Res* 1997;57(2):195–8. [PubMed: 9000552]
15. Cross AJ, Sinha R. Meat-related mutagens/carcinogens in the etiology of colorectal cancer. *Environ Mol Mutagen* 2004;44(1):44–55 doi 10.1002/em.20030. [PubMed: 15199546]
16. Dai Q, Shu XO, Jin F, Gao YT, Ruan ZX, Zheng W. Consumption of animal foods, cooking methods, and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2002;11(9):801–8. [PubMed: 12223422]

17. Le Marchand L, Hankin JH, Wilkens LR, Pierce LM, Franke A, Kolonel LN, et al. Combined effects of well-done red meat, smoking, and rapid N-acetyltransferase 2 and CYP1A2 phenotypes in increasing colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev* 2001;10(12):1259–66. [PubMed: 11751443]
18. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Naturally Occurring Substances - Food Items and Constituents, Heterocyclic Aromatic Amines and Mycotoxins. *IARC Monogr Eval Carcinog Risk Chem Hum* 1993;56:165–242.
19. Alaejos MS, Afonso AM. Factors That Affect the Content of Heterocyclic Aromatic Amines in Foods. *Comprehensive Reviews in Food Science and Food Safety* 2011;10(2):52–108 doi 10.1111/j.1541-4337.2010.00141.x.
20. Yoshida D, Matsumoto T. Amino-alpha-carbolines as mutagenic agents in cigarette smoke condensate. *Cancer Lett* 1980;10(2):141–9. [PubMed: 7006799]
21. Smith CJ, Qian X, Zha Q, Moldoveanu SC. Analysis of alpha- and beta-carbolines in mainstream smoke of reference cigarettes by gas chromatography-mass spectrometry. *J Chromatogr A* 2004;1046(1-2):211–6. [PubMed: 15387190]
22. Wu W, Zhang L, Jain RB, Ashley DL, Watson CH. Determination of carcinogenic tobacco-specific nitrosamines in mainstream smoke from U.S.-brand and non-U.S.-brand cigarettes from 14 countries. *Nicotine Tob Res* 2005;7(3):443–51 doi 10.1080/14622200500125898. [PubMed: 16085512]
23. Hecht SS, Hoffmann D. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. *Carcinogenesis* 1988;9(6):875–84. [PubMed: 3286030]
24. Ohgaki H, Matsukura N, Morino K, Kawachi T, Sugimura T, Takayama S. Carcinogenicity in mice of mutagenic compounds from glutamic acid and soybean globulin pyrolysates. *Carcinogenesis* 1984;5(6):815–9. [PubMed: 6539177]
25. Okonogi H, Ushijima T, Shimizu H, Sugimura T, Nagao M. Induction of aberrant crypt foci in C57BL/6N mice by 2-amino-9H-pyrido[2,3-b]indole (A alphaC) and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx). *Cancer Lett* 1997;111(1-2):105–9. [PubMed: 9022134]
26. Zhang XB, Felton JS, Tucker JD, Urlando C, Heddle JA. Intestinal mutagenicity of two carcinogenic food mutagens in transgenic mice: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and amino(alpha)carboline. *Carcinogenesis* 1996;17(10):2259–65. [PubMed: 8895498]
27. Snyderwine EG, Sadrieh N, King RS, Schut HA. Formation of DNA adducts of the food-derived mutagen 2-amino-9H-pyrido-[2,3-b]indole (A(alpha)C) and bioassay of mammary gland carcinogenicity in Sprague-Dawley rats. *Food Chem Toxicol* 1998;36(12):1033–41. [PubMed: 9862644]
28. Tamano S, Hasegawa R, Hagiwara A, Nagao M, Sugimura T, Ito N. Carcinogenicity of a mutagenic compound from food, 2-amino-3-methyl-9H-pyrido[2,3-b]indole (MeA alpha C), in male F344 rats. *Carcinogenesis* 1994;15(9):2009–15. [PubMed: 7522984]
29. IARC. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Lyon, France 1986;38(Tobacco smoking):37–385.
30. FDA. Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke: Established List. US Department of Health and Human Services, Food and Drug Administration 2012.
31. Holland RD, Taylor J, Schoenbachler L, Jones RC, Freeman JP, Miller DW, et al. Rapid biomonitoring of heterocyclic aromatic amines in human urine by tandem solvent solid phase extraction liquid chromatography electrospray ionization mass spectrometry. *Chem Res Toxicol* 2004;17(8):1121–36 doi 10.1021/tx049910a. [PubMed: 15310244]
32. Yoshida D, Matsumoto T, Yoshimura R, Matsuzaki T. Mutagenicity of amino-alpha-carbolines in pyrolysis products of soybean globulin. *Biochem Biophys Res Commun* 1978;83(3):915–20. [PubMed: 361041]
33. Gross GA, Gruter A. Quantitation of mutagenic/carcinogenic heterocyclic aromatic amines in food products. *J Chromatogr* 1992;592(1-2):271–8. [PubMed: 1583097]

34. Layton DW, Bogen KT, Knize MG, Hatch FT, Johnson VM, Felton JS. Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. *Carcinogenesis* 1995;16(1):39–52. [PubMed: 7834804]
35. Raza H, King RS, Squires RB, Guengerich FP, Miller DW, Freeman JP, et al. Metabolism of 2-amino-alpha-carboline. A food-borne heterocyclic amine mutagen and carcinogen by human and rodent liver microsomes and by human cytochrome P4501A2. *Drug Metab Dispos* 1996;24(4):395–400. [PubMed: 8801053]
36. Frederiksen H, Frandsen H. In vitro metabolism of two heterocyclic amines, 2-amino-9H-pyrido[2,3-b]indole (A(alpha)C) and 2-amino-3-methyl-9H-pyrido[2,3-b]indole (MeA(alpha)C) in human and rat hepatic microsomes. *Pharmacol Toxicol* 2002;90(3):127–34. [PubMed: 12071333]
37. Niwa T, Yamazoe Y, Kato R. Metabolic activation of 2-amino-9H-pyrido[2,3-b]indole by rat-liver microsomes. *Mutation research* 1982;95(2-3):159–70. [PubMed: 6750381]
38. King RS, Teitel CH, Kadlubar FF. In vitro bioactivation of N-hydroxy-2-amino-alpha-carboline. *Carcinogenesis* 2000;21(7):1347–54. [PubMed: 10874013]
39. Tang Y, LeMaster DM, Nauwelaers G, Gu D, Langouet S, Turesky RJ. UDP-glucuronosyltransferase-mediated metabolic activation of the tobacco carcinogen 2-amino-9H-pyrido[2,3-b]indole. *J Biol Chem* 2012;287(18):14960–72 doi 10.1074/jbc.M111.320093. [PubMed: 22393056]
40. Cai T, Yao L, Turesky RJ. Bioactivation of Heterocyclic Aromatic Amines by UDP Glucuronosyltransferases. *Chem Res Toxicol* 2016;29(5):879–91 doi 10.1021/acs.chemrestox.6b00046. [PubMed: 27032077]
41. Pfau W, Schulze C, Shirai T, Hasegawa R, Brockstedt U. Identification of the major hepatic DNA adduct formed by the food mutagen 2-amino-9H-pyrido[2,3-b]indole (A alpha C). *Chem Res Toxicol* 1997;10(10):1192–7 doi 10.1021/tx9701182. [PubMed: 9348443]
42. Frederiksen H, Frandsen H, Pfau W. Syntheses of DNA adducts of two heterocyclic amines, 2-amino-3-methyl-9H-pyrido[2,3-b]indole (MeAalphaC) and 2-amino-9H-pyrido[2,3-b]indole (AalphaC) and identification of DNA adducts in organs from rats dosed with MeAalphaC. *Carcinogenesis* 2004;25(8):1525–33 doi 10.1093/carcin/bgh156. [PubMed: 15059926]
43. Nauwelaers G, Bessette EE, Gu D, Tang Y, Rageul J, Fessard V, et al. DNA adduct formation of 4-aminobiphenyl and heterocyclic aromatic amines in human hepatocytes. *Chem Res Toxicol* 2011;24(6):913–25 doi 10.1021/tx200091y. [PubMed: 21456541]
44. Turesky RJ, Yuan JM, Wang R, Peterson S, Yu MC. Tobacco smoking and urinary levels of 2-amino-9H-pyrido[2,3-b]indole in men of Shanghai, China. *Cancer Epidemiol Biomarkers Prev* 2007;16(8):1554–60 doi 10.1158/1055-9965.EPI-07-0132. [PubMed: 17684128]
45. Konorev D, Koopmeiners JS, Tang Y, Franck Thompson EA, Jensen JA, Hatsukami DK, et al. Measurement of the Heterocyclic Amines 2-Amino-9H-pyrido[2,3-b]indole and 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Urine: Effects of Cigarette Smoking. *Chem Res Toxicol* 2015;28(12):2390–9 doi 10.1021/acs.chemrestox.5b00401. [PubMed: 26574651]
46. Zhang L, Xia Y, Xia B, Nicodemus KJ, McGuffey J, McGahee E, et al. High-throughput and sensitive analysis of urinary heterocyclic aromatic amines using isotope-dilution liquid chromatography-tandem mass spectrometry and robotic sample preparation system. *Anal Bioanal Chem* 2016;408(28):8149–61 doi 10.1007/s00216-016-9917-x. [PubMed: 27687186]
47. Pirkle JL, Bernert JT, Caudill SP, Sosnoff CS, Pechacek TF. Trends in the exposure of nonsmokers in the U.S. population to secondhand smoke: 1988–2002. *Environ Health Perspect* 2006;114(6):853–8. [PubMed: 16759984]
48. Caudill SP, Schleicher RL, Pirkle JL. Multi-rule quality control for the age-related eye disease study. *Stat Med* 2008;27(20):4094–106 doi 10.1002/sim.3222. [PubMed: 18344178]
49. Finkelstein MM, Verma DK. Exposure estimation in the presence of nondetectable values: another look. *AIHAJ* 2001;62(2):195–8. [PubMed: 11331991]
50. Hornung RW, Reed LD. Estimation of Average Concentration in the Presence of Nondetectable Values. *Applied Occupational and Environmental Hygiene* 1990;5(1):46–51 doi 10.1080/1047322X.1990.10389587.

51. Espenship MF, Silva LK, Smith MM, Capella KM, Reese CM, Rasio JP, et al. Nitromethane Exposure from Tobacco Smoke and Diet in the U.S. Population: NHANES, 2007-2012. *Environ Sci Technol* 2019;53(4):2134–40 doi 10.1021/acs.est.8b05579. [PubMed: 30672285]
52. Pirkle JL, Flegal KM, Bernert JT, Brody DJ, Etzel RA, Maurer KR. Exposure of the US population to environmental tobacco smoke: the Third National Health and Nutrition Examination Survey, 1988 to 1991. *JAMA* 1996;275(16):1233–40. [PubMed: 8601954]
53. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. *Environ Health Perspect* 2005;113(2):192–200. [PubMed: 15687057]
54. Fu Y, Zhao G, Wang S, Yu J, Xie F, Wang H, et al. Simultaneous determination of fifteen heterocyclic aromatic amines in the urine of smokers and nonsmokers using ultra-high performance liquid chromatography-tandem mass spectrometry. *J Chromatogr A* 2014;1333:45–53 doi S0021-9673(14)00139-3 [pii] 10.1016/j.chroma.2014.01.057. [PubMed: 24529957]
55. Frederiksen H, Frandsen H. Impact of five cytochrome p450 enzymes on the metabolism of two heterocyclic aromatic amines, 2-amino-9H-pyrido[2,3-b]indole (AalphaC) and 2-amino-3-methyl-9H-pyrido[2,3-b]indole (MeAalphaC). *Pharmacol Toxicol* 2003;92(5):246–8. [PubMed: 12753413]
56. Bellamri M, Le Hegarat L, Turesky RJ, Langouet S. Metabolism of the Tobacco Carcinogen 2-Amino-9H-pyrido[2,3-b]indole (AalphaC) in Primary Human Hepatocytes. *Chem Res Toxicol* 2017;30(2):657–68 doi 10.1021/acs.chemrestox.6b00394. [PubMed: 27976871]
57. Chevereau M, Glatt H, Zalko D, Cravedi JP, Audebert M. Role of human sulfotransferase 1A1 and N-acetyltransferase 2 in the metabolic activation of 16 heterocyclic amines and related heterocyclics to genotoxicants in recombinant V79 cells. *Arch Toxicol* 2017;91(9):3175–84 doi 10.1007/s00204-017-1935-8. [PubMed: 28160022]
58. Carrillo JA, Benitez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. *Br J Clin Pharmacol* 1996;41(6):605–8. [PubMed: 8799528]
59. Gunes A, Ozbey G, Vural EH, Uluoglu C, Scordo MG, Zengil H, et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. *Pharmacogenomics* 2009;10(5):769–78 doi 10.2217/pgs.09.22. [PubMed: 19450128]
60. Rybak ME, Sternberg MR, Pao C- I, Pfeiffer CM. Determination of CYP1A2 Activity in the US Population by Use of Caffeine Metabolite Ratios in Spot Urine Samples: NHANES 2009–2010. *The FASEB Journal* 2016;30(1 Supplement):2711.
61. Walters DG, Young PJ, Agus C, Knize MG, Boobis AR, Gooderham NJ, et al. Cruciferous vegetable consumption alters the metabolism of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in humans. *Carcinogenesis* 2004;25(9):1659–69 doi 10.1093/carcin/bgh164. [PubMed: 15073045]
62. Murray S, Lake BG, Gray S, Edwards AJ, Springall C, Bowey EA, et al. Effect of cruciferous vegetable consumption on heterocyclic aromatic amine metabolism in man. *Carcinogenesis* 2001;22(9):1413–20. [PubMed: 11532863]
63. Turesky RJ, Konorev D, Fan X, Tang Y, Yao L, Ding X, et al. Effect of Cytochrome P450 Reductase Deficiency on 2-Amino-9H-pyrido[2,3-b]indole Metabolism and DNA Adduct Formation in Liver and Extrahepatic Tissues of Mice. *Chem Res Toxicol* 2015;28(12):2400–10 doi 10.1021/acs.chemrestox.5b00405. [PubMed: 26583703]




Figure 1.

Histograms of urinary AaC and MeAaC (ng analyte/g creatinine) among exclusive tobacco smokers and non-users in the NHANES 2013–2014. Green reference line represents median; A panel showed the percent-distribution of urinary AaC among non-users; B panel showed the percent-distribution of urinary AaC among exclusive tobacco smokers; C panel showed the percent-distribution of urinary MeAaC among non-users; D panel showed the percent-distribution of urinary MeAaC among exclusive tobacco smokers.




Figure 2.

Least-square means of urinary AαC concentrations [pg/mL], adjusted for sex, age, race/Hispanic origin, BMI, fasting time, urinary creatinine, diet, and impoverishment (N = 1,760). (Error bars denote 95% confidence intervals). Group ≤ 0.05 ng/mL serum cotinine: participants unexposed to tobacco smoke; Group > 0.05 to ≤ 10 ng/mL serum cotinine: participants presumptively exposed to second-hand tobacco smoke; Exclusive tobacco smokers were further classified based on their cigarettes smoked per day (CPD) consumed.

Table 1. Sample-weighted demographic proportions for AaC (N = 1,792) and MeAaC (N = 1,793) among NHANES 2013–2014 participants.

Variables	AaC ¹			MeAaC ¹		
	Sample Size ²	Percent (SE) ³	Sample Size ²	Percent (SE) ³	Sample Size ²	Percent (SE) ³
Age (years)						
18–39	276	46.7 (3.08)	419	36.0 (1.43)	276	46.7 (3.01)
40–59	264	40.1 (3.17)	347	34.4 (1.78)	264	40.0 (3.03)
60	123	13.3 (1.59)	363	29.6 (1.79)	124	13.3 (1.57)
BMI						
Healthy	222	34.9 (1.79)	337	30.1 (1.86)	223	35.0 (1.81)
Over/Obese	421	62.4 (2.02)	779	69.2 (1.80)	420	62.3 (2.06)
Under	20	2.70 (0.65)	13	0.77 (0.17)	21	2.73 (0.64)
Poverty Income Ratio						
PIR<1	260	28.3 (3.61)	213	11.8 (1.55)	261	28.3 (3.42)
PIR>=1	403	71.7 (3.61)	916	88.2 (1.55)	403	71.7 (3.42)
Race						
Mexican American	43	6.21 (2.25)	190	10.4 (2.21)	43	6.21 (2.26)
Non-Hispanic Black	172	17.0 (2.49)	185	9.13 (1.39)	172	17.1 (2.45)
Non-Hispanic White	349	67.4 (3.85)	478	66.9 (3.70)	351	67.4 (3.80)
Other Hispanic	38	3.52 (1.32)	113	5.52 (0.96)	37	3.46 (1.26)
Other/Multi Race	61	5.84 (1.11)	163	8.03 (0.85)	61	5.85 (1.11)
Sex						
Female	301	45.6 (2.31)	606	52.8 (1.78)	303	45.9 (2.42)
Male	362	54.4 (2.31)	523	47.2 (1.78)	361	54.1 (2.42)

¹ Same data as in stratified serum cotinine regression models.

² Sample size, unweighted.

³ Standard error.

Sample-weighted median (25th, 75th percentile) of urinary AaC (N = 1,792) and MeAaC (N = 1,793) concentrations (creatinine adjusted) by age, sex, body mass index (BMI), and race/Hispanic origin, categorized by smoking status among U.S. population.

Table 2.

Variables	AaC ¹		MeAaC ¹	
	[ng/g creatinine (25th, 75th percentile)]	Non-tobacco users [§]	[ng/g creatinine (25th, 75th percentile)]	Non-tobacco users [§]
All	31.9 [10.2, 79.4]	0.79 [0.45, 1.51]	1.57 [0.35, 4.43]	0.26 [0.16, 0.49]
Age (years)				
18-39	19.7 [5.64, 51.7]	0.79 [0.45, 1.64]	0.90 [0.23, 2.85]	0.23 [0.15, 0.45]
40-59	46.0 [18.5, 86.7]	0.83 [0.43, 1.52]	2.28 [0.53, 5.22]	0.29 [0.17, 0.53]
60	49.5 [18.6, 105.2]	0.77 [0.46, 1.29]	2.44 [0.66, 6.66]	0.28 [0.18, 0.52]
BMI				
Healthy	35.4 [8.87, 74.27]	0.93 [0.54, 1.69]	1.84 [0.33, 4.27]	0.37 [0.20, 0.55]
Over/Obese	30.2 [9.18, 73.3]	0.72 [0.42, 1.35]	1.40 [0.35, 3.96]	0.24 [0.16, 0.46]
Under	84.8 [16.6, 108]	1.41 [0.49, 2.12]	5.60 [1.02, 7.78]	0.68 [0.23, 1.11]
Poverty Income Ratio				
PIR<1	40.6 [15.4, 88.7]	0.69 [0.40, 1.34]	2.17 [0.51, 5.26]	0.22 [0.15, 0.38]
PIR>=1	29.2 [6.68, 71.0]	0.80 [0.46, 1.52]	1.47 [0.30, 4.21]	0.27 [0.17, 0.51]
Race				
Mexican American	5.44 [1.84, 15.71]	0.83 [0.48, 1.62]	0.29 [0.12, 0.53]	0.25 [0.16, 0.48]
Non-Hispanic Black	27.4 [9.24, 50.0]	0.44 [0.31, 0.86]	1.19 [0.32, 2.96]	0.18 [0.13, 0.24]
Non-Hispanic White	38.1 [14.8, 92.4]	0.83 [0.47, 1.55]	1.73 [0.44, 5.27]	0.28 [0.17, 0.52]
Other Hispanic	37.3 [23.3, 67.7]	0.75 [0.47, 1.52]	2.12 [1.17, 3.47]	0.25 [0.15, 0.39]
Other/Multi Race	33.4 [10.8, 51.4]	0.79 [0.55, 1.62]	1.38 [0.35, 3.80]	0.37 [0.21, 0.60]
Sex				
Female	42.5 [15.1, 91.6]	0.86 [0.52, 1.75]	1.94 [0.41, 5.53]	0.34 [0.19, 0.59]
Male	26.3 [6.55, 58.0]	0.70 [0.39, 1.29]	1.47 [0.33, 3.54]	0.21 [0.14, 0.40]

¹ Same data as in stratified serum cotinine regression models.

Detection rates: §: 98.2%; ¶: 39.3%; †: 74.8%; ‡: 4.3%.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3.

Sample-weighted multiple regression results for urinary AaC concentrations [pg/mL] among exclusive smokers from NHANES 2013–2014 participants. The geometric mean of urinary AaC among exclusive smokers used for computing Y is 22.6 pg/mL.

Variables	Exclusive Smokers (N = 663)		
	Slope [95% CI] ¹	Y [95% CI] ²	p-value
Cotinine, serum (ng/mL)	0.0050 [0.0039, 0.0061]	0.113 [0.0900, 0.136]	<.0001
Creatinine, urine (g/mL)	293 [43.0, 543]	4.37E+128 [5.78E+28, 3.31E+228]	0.03
Fasting time (hours)	-0.0227 [-0.0510, 0.0056]	-0.507 [-1.07, 0.0747]	0.11
Age (years)			
18–39	-0.149 [-0.497, 0.199]	-3.13 [-8.45, 4.19]	0.37
40–59	Ref.	.	.
60	0.250 [-0.187, 0.687]	6.40 [-3.18, 20.7]	0.24
Food Group			
High temperature cooked beef (kg)	0.836 [-1.29, 2.96]	29.5 [-15.2, 345]	0.42
High temperature cooked fish (kg)	0.162 [-0.580, 0.905]	3.98 [-9.15, 30.0]	0.65
Meat, poultry, fish, and mixtures (kg)	0.0157 [-0.565, 0.597]	0.358 [-9.13, 16.5]	0.96
Milk and milk products (kg)	-0.152 [-0.586, 0.283]	-3.18 [-9.56, 6.35]	0.47
Eggs (kg)	0.893 [-1.23, 3.01]	32.5 [-14.7, 365]	0.38
Legumes, nuts, seeds (kg)	-0.922 [-3.28, 1.44]	-13.6 [-21.5, 56.0]	0.42
Grain products (kg)	-0.180 [-0.471, 0.112]	-3.71 [-8.14, 2.09]	0.21
Fruits (kg)	-0.0643 [-0.449, 0.321]	-1.40 [-7.71, 7.58]	0.73
Vegetables (kg)	-0.146 [-0.987, 0.694]	-3.07 [-13.6, 19.7]	0.72
Fats, oils, salad dressings (kg)	0.197 [-4.60, 4.99]	4.91 [-22.2, 2.24E+03]	0.93
Sugars, sweets, beverages (kg)	0.0578 [-0.0206, 0.136]	1.34 [-0.321, 3.13]	0.14
BMI			
Healthy	Ref.	.	.
Overweight/Obese	0.140 [-0.186, 0.467]	3.40 [-3.34, 12.5]	0.37
Underweight	-0.116 [-0.930, 0.698]	-2.47 [-13.1, 19.9]	0.77
Poverty income ratio (PIR)			
PIR = 1	Ref.	.	.
PIR <1	0.273 [0.0584, 0.487]	7.08 [1.77, 13.5]	0.02
Race			
Mexican-American	-0.588 [-1.08, -0.0938]	-10.0 [-14.6, -2.82]	0.02
Non-Hispanic black	-0.189 [-0.545, 0.167]	-3.88 [-9.09, 3.35]	0.28
Non-Hispanic white	Ref.	.	.
Other Hispanic	0.212 [-0.379, 0.803]	5.33 [-6.37, 25.5]	0.46
Other/Multi-race	-0.173 [-0.563, 0.217]	-3.58 [-9.30, 4.60]	0.36
Sex			

Variables	Exclusive Smokers (N = 663)		
	Slope [95% CI] ¹	Y [95% CI] ²	p-value
Female	0.221 [-0.0862, 0.530]	5.60 [-1.34, 14.8]	0.15
Male	Ref.		.

Abbreviations: Ref, reference group.

¹The dependent variable, biomarker concentration, was natural log-transformed for the regression model.

² Y is the expected change in biomarker concentration in pg/mL associated with a unit-increase in the predictor, controlling for other predictors in the model and calculated at the overall geometric mean.

Table 4.

Sample-weighted multiple regression results for urinary AaC concentrations [pg/mL] among non-users of tobacco from NHANES 2013–2014 participants. The geometric mean of urinary AaC among non-users used for computing Y is 0.75pg/mL.

Variables	Non-Users (N = 1,129)		
	Slope [95% CI] ¹	Y [95% CI] ²	p-value
Cotinine, serum (ng/mL)	0.171 [0.0771, 0.264]	0.140 [0.0665, 0.220]	0.001
Creatinine, urine (g/mL)	304 [193, 415]	8.13E+131 [4.58E+87, 1.45E+176]	<.0001
Fasting time (hours)	-0.0161 [-0.0256, -0.0066]	-0.0120 [-0.0185, -5.53E-03]	0.003
Age (years)			
18–39	0.0301 [-0.148, 0.208]	0.0230 [-0.0940, 0.161]	0.72
40–59	Ref.	Ref.	.
60	-0.128 [-0.293, 0.0375]	-0.0903 [-0.184, 0.0184]	0.12
Food Group			
High temperature cooked beef (kg)	3.07 [0.337, 5.81]	15.5 [0.561, 201]	0.03
High temperature cooked fish (kg)	-0.501 [-1.07, 0.0736]	-0.296 [-0.484, 0.0209]	0.08
Meat, poultry, fish, and mixtures (kg)	0.245 [-0.155, 0.645]	0.209 [-0.0870, 0.637]	0.21
Milk and milk products (kg)	-0.0927 [-0.298, 0.112]	-0.0667 [-0.185, 0.0757]	0.35
Eggs (kg)	-0.200 [-1.06, 0.662]	-0.137 [-0.474, 0.609]	0.63
Legumes, nuts, seeds (kg)	-0.0525 [-0.892, 0.787]	-0.0385 [-0.423, 0.793]	0.90
Grain products (kg)	-0.0978 [-0.417, 0.222]	-0.0702 [-0.244, 0.163]	0.52
Fruits (kg)	-0.0182 [-0.271, 0.235]	-0.0136 [-0.167, 0.180]	0.88
Vegetables (kg)	-0.431 [-0.775, -0.0863]	-0.264 [-0.396, -0.0812]	0.02
Fats, oils, salad dressings (kg)	1.198 [-0.838, 3.23]	1.74 [-0.369, 15.5]	0.23
Sugars, sweets, beverages (kg)	0.0236 [-0.0170, 0.0642]	0.0180 [-0.0102, 0.0473]	0.23
BMI			
Healthy	Ref.		.
Overweight/Obese	-0.0304 [-0.204, 0.144]	-0.0225 [-0.131, 0.104]	0.72
Underweight	-0.0487 [-0.500, 0.403]	-0.0358 [-0.280, 0.333]	0.82
Poverty income ratio (PIR)			
PIR ≥ 1	Ref.		.
PIR <1	-0.0502 [-0.206, 0.105]	-0.0368 [-0.132, 0.0731]	0.50
Race			
Mexican-American	0.0523 [-0.189, 0.294]	0.0404 [-0.118, 0.238]	0.65
Non-Hispanic black	-0.325 [-0.520, -0.130]	-0.209 [-0.298, -0.102]	0.003
Non-Hispanic white	Ref.		.
Other Hispanic	-0.0235 [-0.253, 0.206]	-0.0175 [-0.157, 0.155]	0.83
Other/Multi-race	-0.147 [-0.280, -0.0141]	-0.103 [-0.178, -0.0184]	0.03
Sex			

Variables	Non-Users (N = 1,129)		
	Slope [95% CI] ¹	Y [95% CI] ²	p-value
Female	-0.0271 [-0.106 0.0513]	-0.0202 [-0.0712, 0.0347]	0.47
Male	Ref.		.

Abbreviations: Ref, reference group.

¹The dependent variable, biomarker concentration, was natural log-transformed for the regression model.

² Y is the expected change in biomarker concentration in pg/mL associated with a unit-increase in the predictor, controlling for other predictors in the model and calculated at the overall geometric mean.